We appreciate the comments by Dr O'Connell and colleagues on our article published in CHEST 1 describing the cumulative incidence and pretransplant risk factors for post-lung transplant renal dysfunction in adult patients with cystic fi brosis (CF).
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To the Editor:
We appreciate the comments by Dr O'Connell and colleagues on our article published in CHEST 1 describing the cumulative incidence and pretransplant risk factors for post-lung transplant renal dysfunction in adult patients with cystic fi brosis (CF).
We agree that serum creatinine concentration alone should not be relied upon solely to assess renal function in CF because of its poor sensitivity. Although the use of glomerular fi ltration rate (GFR) estimating equations, such as the Cockcroft-Gault formula and the abbreviated Modifi ed Diet in Renal Disease (aMDRD) equation, represent improvements compared with serum creatinine alone, as they factor in patient age, weight, and sex, these equations still tend to overestimate renal function in CF compared with gold standard measurement techniques. 2 Patients with CF tend to be malnourished compared with the general population, with less muscle mass per body weight. Low muscle mass leads to reduced creatinine pro duction, which results in overestimation of GFR. 3 The estimated 2-year cumulative incidence of post-lung transplant renal dysfunc tion of 35% derived in our study is conservative, since we used the Cockcroft-Gault formula and have likely overestimated renal func tion. Future studies are required to identify more sensitive markers of renal function with less reliance on serum creatinine.
We also agree that patients with CF have several unique risk factors for the development of renal dysfunction posttransplant, which may increase their risk relative to patients with idiopathic pulmonary fi brosis or COPD. However, we are not aware of any studies that have specifi cally compared the risk of renal dysfunction in these recipient populations. Our study did not focus on post-lung transplant risk factors, but we appreciate Dr O'Connell and colleagues pointing out that oxalate nephropathy and pigmented tubulopathy are well-recognized histopathologic fi ndings following renal biopsy in the early posttransplant period and are likely related to perioperative stressors such as dehydration, hypoxia, and antibiotics. 4 Our analy sis excluded patients diagnosed with renal dysfunction in the fi rst month post-lung transplant to reduce the chance of includ ing acute cases. Our study found that CF-related diabetes requir ing insulin is an important pretransplant risk factor and likely plays an important role in renal function loss in the late posttransplant period. This is in keeping with a published renal biopsy series, which dem onstrated that histopathologic fi ndings responsible for late epi sodes of renal function loss were primarily vascular (ie, diabetic glomerulosclerosis). 4 A large registry-based study has demonstrated that post-lung transplant renal dysfunction is associated with worse post-lung transplant survival. 5 Therefore, further studies are needed targeting modifi able risk factors in the CF population. 
Bradley S. Quon , MD
Diastolic Dysfunction With Nondilated Left Atrium
To the Editor:
We read with great interest the article on cardiac diastolic dysfunction in patients with pulmonary arterial hypertension by Tonelli et al 1 published in CHEST (June 2012). We appreciate their original and interesting contribution, especially when there is limited knowledge on the topic. Echocardiography is the most commonly used method for studying diastolic dysfunction. However, we should keep in mind that current echocardiographic diastolic classifi cation may not be suited to respiratory patients because in these patients the volume of the left atrium is decreased, as Tonelli et al 1 and other authors 2 have reported . In most patients with diastolic dysfunction, the dysfunction occurs when the left atrium is dilated, refl ecting the cumulative effects of fi lling pressures over time. This dilatation is a key point in the diagnosis of diastolic dysfunction, even in mild (or grade I type) cases. In specifi c patents with a nondilated left atrium, caution should be exercised when diastolic classifi cation is applied.
On the other hand, echocardiographic diastolic classifi cation is complex, and sometimes the parameters obtained may be discordant; thus, classifi cation into diastolic stages can be diffi cult. When diastolic dysfunction is graded by experienced observers according to current guidelines, 3 interobserver variability and accuracy depend on how each investigator resolves confl icting observations that make the classifi cation into one specifi c type of diastolic dysfunction diffi cult. It would be interesting to learn if the authors experienced discrepancies with regard to the diastolic Therapeutics, Aptalis, Pharmaxis Ltd, and INSMED Inc investigators meetings, but none of these activities relate to the topic of this manuscript. Dr Goss has received travel money and research grant money from INSMED Inc to attend investigator meet ings and integrate a symptom questionnaire into a clinical trial. He has also received honoraria from Hoffman-La Roche, Inc and Johns Hopkins University for CME courses and course material. He has also received honoraria donated to CF research to attend an advisory meeting with KaloBios Pharmaceuticals, Inc. Drs Quon and Mayer-Hamblett have reported that no potential confl icts of interest exist with any companies/organizations whose products or services may be dis cussed in this article . 
